Zoe Johnson, ACA

Zoë has over 20 years of industry experience in immune mediated diseases, including oncology, hematology, autoimmunity and inflammation. She has successfully led both small and large molecule programs through preclinical research and into clinical development. Zoë is the Chief Scientific Officer at Affivant.
Zoë holds a PhD in pharmacology from King’s College, London and received her honors degree in biological sciences from the University of Manchester, UK. Her experience includes leadership positions at UCB, Merck, Novimmune and iOnctura